{"id":"NCT01986114","sponsor":"Sumitomo Pharma Co., Ltd.","briefTitle":"A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.","officialTitle":"A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-29","primaryCompletion":"2018-02-08","completion":"2018-02-17","firstPosted":"2013-11-18","resultsPosted":"2019-07-23","lastUpdate":"2022-04-12"},"enrollment":495,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I Disorder"],"interventions":[{"type":"DRUG","name":"SM-13496","otherNames":["Lurasidone"]}],"arms":[{"label":"SM-13496 20-120mg","type":"EXPERIMENTAL"}],"summary":"The study evaluates the long-term efficacy and safety of SM-13496 in patients with bipolar I disorder.","primaryOutcome":{"measure":"Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)","timeFrame":"28, 52 weeks","effectByArm":[{"arm":"SM-13496 20-120mg (Overall, 28 Weeks)","deltaMin":352,"sd":null},{"arm":"SM-13496 20-120mg (Japan, 52 Weeks)","deltaMin":169,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":8,"countries":["Japan","Lithuania","Malaysia","Philippines","Russia","Slovakia","Taiwan","Ukraine"]},"refs":{"pmids":["34342746","33321381"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":495},"commonTop":["Akathisia","Nasopharyngitis","Somnolence","Nausea","Headache"]}}